key: cord-1021807-pqzu10vu
authors: Taylor, K.; Das, S.; Pearson, M.; Kozubek, J.; Pawlowski, M.; Jensen, C. E.; Skowron, Z.; Moller, G. L.; Strivens, M.; Gardner, S.
title: Analysis of Genetic Host Response Risk Factors in Severe COVID-19 Patients
date: 2020-06-19
journal: nan
DOI: 10.1101/2020.06.17.20134015
sha: 62dd79497a21a78c9256161ae00bb92b41dc4153
doc_id: 1021807
cord_uid: pqzu10vu

BACKGROUND Epidemiological studies indicate that as many as 20% of individuals who test positive for COVID-19 develop severe symptoms that can require hospitalization. These symptoms include low platelet count, severe hypoxia, increased inflammatory cytokines and reduced glomerular filtration rate. Additionally, severe COVID-19 is associated with several chronic co-morbidities, including cardiovascular disease, hypertension and type 2 diabetes mellitus. The identification of genetic risk factors that impact differential host responses to SARS-CoV-2, resulting in the development of severe COVID-19, is important in gaining greater understanding into the biological mechanisms underpinning life-threatening responses to the virus. These insights could be used in the identification of high-risk individuals and for the development of treatment strategies for these patients. METHODS As of June 6, 2020, there were 976 patients who tested positive for COVID-19 and were hospitalized, indicating they had a severe response to SARS-CoV-2. There were however too few patients with a mild form of COVID-19 to use this cohort as our control population. Instead we used similar control criteria to our previous study looking at shared genetic risk factors between severe COVID-19 and sepsis, selecting controls who had not developed sepsis despite having maximum co-morbidity risk and exposure to sepsis-causing pathogens. RESULTS Using a combinatorial (high-order epistasis) analysis approach, we identified 68 protein-coding genes that were highly associated with severe COVID-19. At the time of analysis, nine of these genes have been linked to differential response to SARS-CoV-2. We also found many novel targets that are involved in key biological pathways associated with the development of severe COVID-19, including production of pro-inflammatory cytokines, endothelial cell dysfunction, lipid droplets, neurodegeneration and viral susceptibility factors. CONCLUSION The variants we found in genes relating to immune response pathways and cytokine production cascades, were in equal proportions across all severe COVID-19 patients, regardless of their co-morbidities. This suggests that such variants are not associated with any specific co-morbidity, but are common amongst patients who develop severe COVID-19. Among the 68 severe COVID-19 risk-associated genes, we found several druggable protein targets and pathways. Nine are targeted by drugs that have reached at least Phase I clinical trials, and a further eight have active chemical starting points for novel drug development. Several of these targets were particularly enriched in specific co-morbidities, providing insights into shared pathological mechanisms underlying both the development of severe COVID-19, ARDS and these predisposing co-morbidities. We can use these insights to identify patients who are at greatest risk of contracting severe COVID-19 and develop targeted therapeutic strategies for them, with the aim of improving disease burden and survival rates.

Coronavirus disease 2019 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major threat to public health. As of 16 th June 2020, there are estimated to be over 8 million confirmed cases globally, resulting in approximately 437,000 deaths worldwide 1, 2 . Although many who develop the disease present with only mild symptoms, reports from multiple international health systems have shown that up to 20% of individuals testing positive for COVID-19 go on to develop severe forms of the disease that may require hospitalization.

Significant associations of disease severity risk have been observed with epidemiological factors including age, sex, blood group and ethnicity in addition to co-morbidity with many common conditions such as cardiovascular disease, diabetes, hypertension and chronic pulmonary diseases including asthma 3 . It would be clinically useful to be able to identify the features that result in differential host responses, particularly those that predispose some patients to developing severe COVID-19. In the context of management of at-risk populations, prior to an effective and widely available vaccine, such insights could have great utility in developing new detection, protection and treatment strategies targeted specifically at these high-risk individuals.

In our previous paper, we explored the shared risk factors between sepsis (a major clinical feature in hospitalized COVID-19 patients) and severe COVID-19 disease 4 . We observed that 59% of hospitalized COVID-19 cases also have sepsis 5 , and that the two diseases share similar co-morbidity risks 6 . In that study we identified 70 risk-associated genes in a sepsis population and found significant overlap in genetic risk variants between sepsis patients and those hospitalized with severe COVID-19.

As more data from COVID-19 patients has become available in the UK Biobank 7,8 , we are now able to investigate the host response genetic risk factors directly, using genotype datasets from 779, 877 and 929 patients hospitalized with severe COVID-19 and comparing them against healthy controls. In this study, we have sought to identify the risk variants associated directly with severe COVID-19 patients, to gain insight of the underlying pathology and disease mechanisms in relation to this patient group.

COVID-19 test records were downloaded from the UK Biobank (data releases 18 May, 26 May and 6 June, 2020) 7, 8 . The 18 May 2020 dataset included 5,657 test records relating to 3,002 individuals in UK Biobank. Of these, 1,073 patients had at least one positive COVID-19 test record, including 818 patients who were hospitalized and 255 who tested positive but were not hospitalized. In accordance with guidance from UK Biobank, we classified those 818 patients who were hospitalized after testing positive with COVID-19 as having a severe form of the disease and the 255 who were not hospitalized as having the mild form of the disease.

The analysis was conducted as a case-control study. After quality control and removal of samples with missing data, we assigned as cases 779 patients (442 males, 337 females) who had been hospitalized with severe COVID-19. Of these severe cases, 62% had one or more of the most common co-morbidities associated with high severe COVID-19 risk ( Figure 1 ).

The most prevalent co-morbidity was hypertension (50%), followed by chronic respiratory disease (22%), diabetes (20%) and cardiovascular disease (18%). 248 (32%) patients were reported having two or more co-morbidities. 291 severe COVID-19 cases had none of these co-morbidities. In comparison, these co-morbidities were found to be less prevalent in the mild cases and an age and gender-matched random selection of the UK Biobank population (Figure 1 ).

Boxplot showing the incidence of five co-morbidities associated with high COVID-19 risk (cardiovascular disease, hypertension, diabetes, chronic respiratory diseases and Alzheimer's disease) among the May 18, 2020 severe COVID-19 patients, sepsis controls, mild COVID-19 patients and 77,900 randomly selected UK Biobank patients that were age and gender-matched with the severe COVID-19 patients.

Due to the limited number of patients with confirmed mild disease we were unfortunately not able to use this cohort directly as our control set due to its small size and lack of statistical power. We therefore adopted similar control cohort criteria to our previous sepsis study 4 , based on evidence of shared risk factors and that severe COVID-19 patients often present with a similar pattern of co-morbid chronic conditions to those with sepsis. We selected patients who had not developed sepsis in spite of having been exposed to the most common sepsis-causing pathogens as well as having at least one of the most common chronic comorbidities known to increase a patient's risk of developing sepsis and COVID-19 ( Figure 2 ).

Incidence of co-morbidities by ICD-10 code from UK Biobank in the May 18, 2020 severe COVID-19 dataset (n= 2,332, 1:2 case control ratio with 779 cases and 1,553 controls).

We selected the oldest possible patients (as age is also a critical phenotypic risk factor for the severe form of COVID-19) with the highest number of co-morbidities. Controls were therefore selected for a lack of disease given maximum risk and exposure, and were gender-matched against the severe COVID-19 cases in the ratio 2:1. The exact control criteria and distribution of the comorbidities in cases are described in the Appendix.

This set of patients represents the most similar available control cohort who could reasonably be expected to have some genetic protective effect against developing severe COVID-19 (or to lack any such risk factors). By selecting controls with a higher prevalence of similar chronic co-morbidities, we seek to ensure that the severe COVID-associated signal observed is not simply caused by the co-morbidities represented in the patient set but has the potential to be a true COVID-19 related enrichment.

After quality control (removal of SNPs with <95% coverage across subjects), the genotype data for the two cohorts contained 542,245 SNPs. The age distribution of cases and controls is shown in Figure 3 . Having generated our case-control dataset, we analyzed it using the precisionlife platform to identify risk-associated SNPs and genes that were strongly associated in the severe COVID-19 disease cohorts. This platform identifies high-order, diseaseassociated combinations of multi-modal (e.g. SNPs, transcriptomic, epidemiological or clinical) features at whole genome resolution in large patient cohorts. It has been validated across multiple different disease populations 9, 10, 11 . This type of analysis is intractable to other existing methods due the combinatorial explosion posed by the analysis of large numbers of patients with combinatorial non-linear additive combinations of features per patient.

When applied to genomic data, precisionlife finds high-order epistatic interactions (multi-SNP genotype signatures -typically of combinatorial order between 3-8) that are significantly more predictive of patients' phenotype than those identified using existing single SNP based methods. When the individual SNPs making up these signatures are assessed individually across the whole population, they may fall below the GWAS (genome-wide association study) significance thresholds. However, we have demonstrated that when evaluated in combination with each other using multiple statistical validation techniques, these SNPs can be highly significant in particular disease sub-populations. The phenotype to which the signatures are associated in this context might be disease status, progression rate, therapy response or other, depending on the data available and study design.

We used the platform to find and statistically validate combinations of SNPs that together are strongly associated with the severe COVID-19 disease diagnosis. Analysis and annotation of these COVID-19-associated combinatorial genomic signatures took less than a day to complete, running on a dual CPU, 4 GPU compute server. The signatures identified by the analysis were then mapped to the human reference genome 12 to identify disease-associated and clinically relevant target genes. A semantic knowledge graph derived from multiple public and private data sources was used to annotate the SNP and gene targets, including relevant tissue expression, chemical activity/tractability for gene targets, functional assignment and disease-associated literature. This provides contextual information to test the targets against the 5Rs criteria of early drug discovery 13 and allows us efficiently to form strong, testable hypotheses for their mechanism of action in driving severe, life-threatening host responses to COVID-19 infection.

All of the significant disease signatures were traced back to the cases in which they were found and were associated with selected attributes such as case co-morbidities and COVID-19 test records. This generated a high-resolution stratification of severe COVID-19 patient subgroups and enabled further analysis of the different underlying factors relating to their specific forms of the disease.

Subsequently, UK Biobank added the COVID-19 test records of 1,508 individuals in data release 26 May, 2020 and 1,607 individuals in data release 6 June, 2020 8 . Of these, 401 patients were tested positive and 158 of them were hospitalized. We repeated our analysis on these two updated datasets with a higher number of controls to make the analysis more robust (see Appendix). 50 (~70%) of the genes identified in our initial analysis were identified in more than one subsequent analysis (highlighted in bold in the gene tables) and therefore have an additional replication.

Using the severe COVID-19 dataset to perform a standard PLINK 14 GWAS analysis revealed no significant SNPs ( Figure 4 ) using a genome-wide significance threshold of p<5e-08. The lowest SNP PLINK p-value reported was 9.02e-08. When the same May 18, 2020 severe COVID-19 patient dataset was run using the precisionlife platform, we identified 3,515 combinations of SNP genotypes representing different combinations of SNP genotypes that were highly associated with the severe COVID-19 patient cohort ( Table 1 ). The majority (n = 3,494) of SNPs were found in combinations with 5 or more SNP genotypes, and as such could not have been found using standard GWAS analysis methods. All of the SNP genotypes and their combinations were scored using a Random Forest (RF) algorithm based on a 5-fold crossvalidation method to evaluate the accuracy with which the SNP genotype combinations predict the observed case: control split. 156 SNPs were scored by the RF algorithm, indicating that they accurately predict the differences between cases and controls ( Figure 5A ). The chromosomal distribution of the critical SNPs is shown in aggregate in Figure 5B . Clustering the SNPs by the patients in whom they co-occur allows us to generate a disease architecture of severe COVID-19 patients, providing useful insights into patient stratification. We can use this to find genes and biological pathways that are associated with patient sub-populations and co-morbidities, enabling the development of disease biomarkers and precision medicine strategies. Figure 6 : Disease architecture of the severe COVID-19 patient population generated by the precisionlife platform. Each circle represents a disease-associated SNP genotype, edges represent co-association in patients, and colours represent distinct patient sub-populations.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 19, 2020. Genes . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 19, 2020. .

Our analysis identified 68 protein-coding genes that were strongly associated with the disease phenotype in patients who developed severe COVID-19. To date, nine of these genes have already been linked to differential COVID-19 host responses in various studies, providing validation for our hypothesis-free approach comparing severe COVID-19 patients against sepsis-free controls. We found several biological pathways and processes that were common in across the 68 COVID-associated genes, including T cell regulation and host pathogenic responses, inflammatory cytokine production, and lipid formation and endothelial cell function ( Figure 9 ). We identified twelve genes that are associated with host immune response to viral infections, including SARS-CoV-2 ( Table 2) . Variants in several of these genes have been associated with increased infectivity to these strains. Genes marked in bold represent those that were further validated in subsequent analyses using the updated severe COVID-19 cases. Our analysis also revealed five genes regulating pro-inflammatory pathways such as necroptosis, reactive oxygen species (ROS) production and cytokine signalling (Table 3) . 23 Mixed lineage pseudokinase Activator of TNF-induced necroptosis, high expression results in necrotic cell death following coronavirus infection NRROS 24 Negative regulator of reactive oxygen species (ROS)

Limits phagocytic ROS and pro-inflammatory cytokine production during host immune response RAB3C 25 Rab GTPase RAB3C increases cells' ability to release IL-6 and activate the JAK2-STAT3 pathway. RBM47 26 RNA binding motif protein Promotes IL-10 production in B cells, repressed by TGF-β SEMA5A 27 Semaphorin 5A High levels of Sema5A are associated with high IFN-ϒ and low IL-4 expression There were also six genes associated with severe COVID-19 patients that play central roles in lipid droplet biology, as well as having high expression in adipose tissue, correlating with serum lipid levels and coronary artery disease (Table 4 ). 28 Cell death inducing DFFA like effector Co-localizes with perilipins, highly expressed in brown adipose tissue MACROD2 29 Mono-ADP ribosylhydrolase Highly associated with VAP-1 in human adipose tissue PLIN4 30 Perilipin 4 Lipid droplet protein, highly expressed in white adipose tissue, high expression results in cardiac steatosis SLIT3 31 Slit guidance ligand 3 High expression in adipose tissue controlled by Prdm16 expression. Upregulated in obese patients. TMEM159 32, 33 Promethin Activated by peroxisome proliferator-activated receptor γ1 (PPARγ1), partners with seipin to regulate lipid droplet organization XKR6 34 XK-related 6 SNP association with serum lipid levels and risk of CAD In addition to this, our analysis revealed twelve more genes that may be implicated in the vascular complications seen in COVID-19 (Table 5) . These genes are all highly expressed in the cardiovascular system, modulating cardiac function and endothelial cell homeostasis. 35 Anthrax toxin receptor 1, type I transmembrane protein (TEM8)

Loss of ANTXR1 results in endothelial basement membrane loss and leaky blood vessels HOPX 36 Hop homeodomain protein, cofactor Acts via serum response factor (SRF), modulating the expression of cardiac genes and stress-induced cardiac hypertrophy MCUB 37 Mitochondrial calcium uniporter Role in cardiac homeostasis, response to cardiac stress including ischemia PIGX 38 Phosphatidylinositol glycan anchor biosynthesis class X Associated with hypertension. Forms a complex with PIG-M that regulates several processes, including maintenance of arterial blood pressure. Acts via apelin receptor signalling. PRKCB 39 Protein kinase C beta form, protein kinase Variety of different cellular functions, including endothelial cell proliferation and insulin signaling PLS3 40 Plastin-3 Induced by angiotensin II in endothelial cells to promote cell migration RAP1GAP2 41, 42 GTPase activator for RAP-1A

Regulates platelet granule secretion and aggregation RBM47 43 RNA binding motif protein Missense variant is associated with hypertension SEMA5A 44 Semaphorin 5A High Sema5A expression increased endothelial cell proliferation and angiogenesis and decreased apoptosis SLIT3 45 Slit guidance ligand 3 Upregulation associated with endothelial cell dysfunction in pulmonary hypertension SORCS2 46 Sortilin-related VPS10 domain-containing receptor 2 (SorCS2), oxidative stress response gene SorCS2 releases endostatin, an endogenous inhibitor of endothelial cell proliferation and angiogenesis SRD5A1 47 Steroid 5 alpha-reductase 1, catalyzes the production of androgen dihydrotestosterone

Androgens have been linked to peripheral artery disease and macrophage modulation . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06.17.20134015 doi: medRxiv preprint Amongst other cancer-associated genes, we identified nine risk-associated genes that directly interacted with the Wnt/β-catenin signaling pathway (Table 6 ). With the exception of KRAS and SLC9A9, all of the proteins encoded by these genes act as endogenous inhibitors of the pathway. 48 KRAS proto-oncogene, GTPase Activates the Wnt/β-catenin pathway MACROD2 49 Mono-ADP ribosylhydrolase Suppresses GSK-3β/β-catenin signaling PCDH17 50 Protocadherin 17, member of the cadherin superfamily Acts as a tumour suppressor in breast cancer, inhibiting the Wnt signaling pathway PRKCB 51 Protein kinase C beta form, protein kinase Promotes the phosphorylation of β-catenin PTPRK 52 Protein tyrosine phosphatase (PTP) receptor, type K

Redistributes and inhibits the transcriptional activity of β-catenin RRM2 53 Ribonucleotide reductase regulatory subunit M2

Downregulation of RRM2 suppresses the activity of β-catenin and the Wnt signaling pathway SLC9A9 54 Solute carrier family 9

Upregulates beta-catenin SLIT3 55 Slit guidance ligand 3 Suppresses GSK3β/β-catenin pathway Finally, our analysis identified four genes that have previously been associated with increased risk of developing Alzheimer's disease (AD), including MAPT, the key gene underlying tau pathology (Table 7 ). Out of the total 68 genes, nine are targeted by clinical candidates that have been evaluated in Phase I clinical trials and beyond (see Appendix). These could potentially form the basis of repurposing therapies, after evaluating factors such as safety and pharmacology data. A further eight targets have active chemistry in ChEMBL 56 , meaning they have active chemical starting points for novel drug development (see Appendix). We can also extend our search for repurposing candidates by looking into known gene interactions to find other more tractable targets in implicated in the same biological pathway.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 19, 2020. . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06.17.20134015 doi: medRxiv preprint

Grouping the 68 genes by common biological functions revealed that many are involved in processes that have also been linked to aberrant host responses to COVID-19, such as the pro-inflammatory cytokine storm and immune system dysregulation, as well as lipid droplet formation and endothelial cell dysfunction.

The host immune response must maintain a balance between effective viral clearance and limiting the immune response to prevent chronic inflammation and collateral tissue damage. In many patients who develop severe COVID-19 reactions and acute respiratory distress syndrome (ARDS) there is evidence of dysregulated cytokine production, resulting in increased levels of proinflammatory mediators including IL-1, IL-6, IL-8, CXCL-10 57 , causing pathological features such as inflammatory cell infiltration, pulmonary edema and sepsis 58 .

From the number of genes we found relating to immune response pathways and cytokine production cascades, it is clear that patients who develop severe COVID-19 and ARDS may have innate genetic variants that prevent this balance from being struck. These variants were found in equal proportions across all severe COVID-19 patients, regardless of their co-morbidities. This suggests that variants in these genes may not be associated with any specific co-morbidity, but are common amongst many patients who develop severe COVID-19.

HOPX regulates a variety of different cellular processes, including cardiac development and myogenesis 36 . However, it was reported in a recent COVID-19 study as part of a selection of genes upregulated in expanded CD8+ T cells in patients with mild COVID-19 59 . These expanded CD8+ effector T cells likely represent SARS-CoV-2-specific T cells, indicating greater efficiency in viral clearance in those patients. However, it is also necessary for Th-1 persistence and resistance to apoptosis, driving chronic inflammation and autoimmune mechanisms 60 . This exemplifies the delicate balance between establishing an effective host immune response necessary for viral clearance and preventing the development of chronic inflammation that results in collateral tissue damage. It seems likely that patients who develop severe COVID-19 may have an inherent imbalance in these factors.

Similarly, we identified SNP variants in ITK that were highly associated with severe COVID-19. High ITK expression is associated with Th2-driven diseases such as allergic asthma, causing pro-inflammatory cytokine production, eosinophil infiltration and production of mucus 61 . A range of potent and selective inhibitors (both small molecule and biologic) of ITK have been developed by several pharmaceutical companies 62, 63 . No selective ITK inhibitors have progressed beyond preclinical testing to date, although ibrutinib -a joint ITK and BTK inhibitor -is currently licensed for use in B cell malignancies and as also demonstrated efficacy in the treatment of leishmaniasis. Data collected from several clinical trials indicate that ibrutinib is reasonably welltolerated by patients 64 . Inhibition of ITK diminishes lung injury, cytokine production and inflammation in a mouse model of asthma 65 . Many of the pro-inflammatory cytokines, such as IFNγ, IL-2, and IL-17, blocked by ITK inhibition are raised in patients with ARDS 66, 67 . Furthermore, use of a selective ITK inhibitor blocked HIV cell entry, transcription and particle formation, effectively reducing viral replication 68 .

A study has found that MLKL is implicated in necrotic cell death following infection with a neurovirulent human coronavirus (HCoV) 69 . Whilst MLKL-induced necrosis may be useful in limiting viral replication, increased necroptosis can also lead to increased inflammation and tissue damage. SNP variants in MLKL could be predisposing patients to severe COVID-19 in one of two ways; with under-functioning protein resulting in poor viral clearance, or through over-expression and over-activation of the necroptotic inflammatory response resulting in organ damage. The SNP variant identified in MLKL was found in the highest scoring 20% of the significant genes in the severe COVID-19 dataset and is present in 251 cases. It is not highly associated with any of the most common co-morbidities found in this dataset. Necrosulfonamide (NSA) is a specific inhibitor of MLKL that potently suppresses necroptosis 70 . Inhibition of this pathway using NSA decreases pro-inflammatory cytokines such as IL-1β, IL-6 and IL-17A in a way that was protective in a model of psoriasis. High levels of IL-1β and IL-6 have both been observed in cases with severe COVID-19 71 . Unfortunately, NSA has only ever been evaluated in preclinical trials, so there is no safety or toxicology data in humans available. NRROS (LRRC3) is an inhibitor of multiple toll-like receptors (TLR) and subsequent NF-ĸB signalling, acting as a brake on proinflammatory cytokine production 72 . NRROS also limits the amount of reactive oxygen species (ROS) produced by phagocytes during the innate immune response, thereby limiting tissue damage caused whilst defending against invading pathogens. It could therefore be hypothesized that SNP variants in this gene, limiting its activity, could make individuals more susceptible to COVID-19-induced inflammatory damage 73 . This is supported by the evidence that Lrrc33-/-mice suffered from increased organ damage as a result of greater pro-inflammatory signalling when challenged with LPS. There are currently no specific small molecule activators of NRROS in publicly-available databases, however a number of chemical agents have been shown to increase the . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 19, 2020. . expression of both the protein and mRNA forms of this gene which may provide chemical starting points for novel drug discovery 74 .

RAB3C may be driving inflammation by inducing the release of IL-6 and activation of the IL-6/JAK2/STAT3 pathway, driving the production of pro-inflammatory cytokines 25, 75 . Ruxolitinib -a JAK2 inhibitor -has been shown to mitigate the effects of RAB3Cinduced IL-6 release 25 . Ruxolitinib is currently being trialled as a treatment for respiratory distress caused by SARS-CoV-2 76 .

Endothelial dysfunction and vascular inflammation, resulting in neutrophilic infiltration, endothelial cell apoptosis and tissue edema, is seen in patients who develop ARDS from SARS-CoV-2 infection 77 . Many of the common co-morbidities associated with severe COVID-19 development, -such as diabetes, hypertension and cardiovascular disease -are already associated with vascular inflammation and endothelial cell dysfunction pathological features 78, 79, 80 . It is therefore unsurprising that these patients are at higher risk of developing severe COVID-19.

Many of the risk-associated SNPs that we found that were related to these pathological pathways were found in severe COVID-19 patients who had at least one of these co-morbidities. However, we controlled for this effect by co-morbidity-matching these cases against the sepsis-free controls, meaning that these SNPs are not likely to be just be artefacts of the co-associated comorbidity, but a differentiating factor in the development of severe COVID-19 and ARDS.

Helios (IZKF2) expression is used as a marker for regulatory T cells (Tregs), and therefore has an important role in self-tolerance and regulating autoimmunity 81 . Decreased levels of Helios+ Tregs have been observed in patients with hypertension and rheumatoid arthritis, with lower expression levels correlating with increased inflammatory markers 82 . Tregs may protect against hypertension by limiting vascular inflammation through suppression of effector T cells 83, 84 . Furthermore, our analysis revealed that variants in IZKF2 were disproportionately co-associated with patients with hypertension ( Figure 10 ). This adds further evidence to the association between vascular inflammation, severe COVID-19 and cardiovascular hypertensive co-morbidities.

MCUB encodes one of the pore-forming subunits of the mitochondrial Ca 2+ uniporter (MCU). MCUB is a necessary part of a protective response against mitochondrial Ca 2+ overload during cardiac injury and ischemia 85 . Mcub -/-mice displayed increased cardiac remodelling and ischemic injury as a result of increased mitochondrial Ca 2+ uptake 86 . Although more research is required to fully understand the role of MCUB in severe COVID-19 pathogenesis, a decreased level of serum calcium has been suggested as a biomarker for increased COVID-19 severity and ARDS 87 .

PKCβ (PRKCB) is a serine/threonine protein kinase that is activated by calcium. It has a range of functions, including B cell activation, endothelial cell proliferation and activation of apoptosis 35 . However, PKCβ has also been linked to a number of different vascular diseases, including atherosclerosis, diabetes and hypertension 88, 89 . We find that in our case population, the risk-associated SNP found in PRKCB was found in 165 severe COVID-19 cases (penetrance = 20.2%), and was present in 45% of patients with cardiovascular disease and 51% of patients with hypertension. High levels of PKCβ result in increased vascular inflammation, endothelial dysfunction and oxidative stress, all of which have been found in patients with severe COVID-19 90, 91 . PKCβ also drives the accumulation of cholesterol in macrophages, leading to foam cell development and macrophage dysregulation 92 . Therefore, inhibition of PKCβ could help to reverse some of the vascular-related pathology, contributing to sepsis development and multi-organ failure, that is seen in severe COVID-19 patients. Ruboxistaurin (LY333531) is a selective PKCβ inhibitor that has been trialled as an anti-diabetic drug to reduce vascular and retinal complications that certain diabetic patients develop 93 . It has reasonable pharmacokinetic and toxicology data, as it can be orally administered and is well-tolerated by patients 94, 95 . However, it was discontinued and has failed to progress beyond Phase III clinical trials 96 .

We also found genes, including CIDEA and PLIN4, that protect against insulin resistance (IR). IR results in increased cardiovascular inflammation and oxidative stress, contributing to atherosclerotic plaque formation and hypertension 97 . High Cidea expression decreases circulating fatty acid levels by increasing the level of triglycerides stored in lipid droplets. This helps to protect against insulin resistance 98 . The anti-diabetic drug rosiglitazone may have insulin sensitising effects by increasing the expression of both Cidea and perilipins 28 . Our analysis identified CIDEA and a perilipin, PLIN4, as being highly associated with severe COVID-19 patients. SNPs in CIDEA were found in one of the highest proportions in severe COVID-19 patients, particularly in patients with cardiovascular and hypertensive diseases ( Figure 10 ). This indicates that insulin resistance is a contributing factor to vascular inflammatory pathologies that may predispose patients to developing ARDS in response to SARS-CoV-2.

Finally, variants in GFRA1 are within the highest 10% of genes most associated with hypertensive patients in our case population. GFRα1, encoded by GFRA1, plays a key role in glial cell line-derived neurotrophic factor (GDNF)-mediated signalling 99 . GFRα1 induces autophagy via activation of the RET/AMPK signalling pathway independently from its interaction with GDNF. In the early stages of sepsis, autophagy is a protective mechanism employed by cells to remove damaged proteins, reduce mitochondrial dysfunction-induced inflammation and eliminate pathogens 100, 101 . Furthermore, inhibition of autophagy in mouse models of . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06.17.20134015 doi: medRxiv preprint sepsis results in increased mortality. Selective agonists of GFRα1 are under development 102 , which may help to protect against sepsis-induced tissue damage in the early stages of the disease.

There is increasing evidence that lipid dysfunction plays a role in COVID-19 pathogenesis. Lipid droplets (LD) play a key role in viral pathogenesis, as intracellular lipid stores are crucial for viral replication and assembly 103 . LD proteins have been associated with particle load and pathogenicity in other virus strains, including hepatitis C, dengue and rotavirus 104 . It has also been shown that coronaviruses use host cellular lipid machinery during replication 105 .

We identified six genes associated with lipids and adipose tissue, with three genes directly involved in lipid droplet formation (Table 4) . A different member of the perilipin family (PLIN3) is used by hepatitis C virus (HCV) for steatosis development and viral assembly 106 , with PLIN3 inhibition resulting in decreased viral particle release from host cells 107 . Promethin (TMEM159) has also been recently identified as lipid droplet organiser (LDO) in partnership with seipin 33 . Although promethin has not been studied in the context of viral disease, overexpression of its co-associated protein seipin results in significantly reduced viral particle secretion and infectivity in a model of hepatitis C 108 .

Our analysis identified nine genes that regulate either the Wnt or β-catenin components of the Wnt/β-catenin pathway.

There is a long-established role of the Wnt gene-family and the associated signally pathway in embryogenesis and therefore its relationship to developmental disorders and carcinogenesis. However recent work 109, 110 shows an emerging and complex picture of the role of Wnt genes in host cell defence mechanisms, the modulation of inflammatory cytokine production and connections between innate and adaptive immune systems. The role of these ligands varies within the family members and their relation to βcatenin.

Wnt/β-catenin signalling has both anti-and pro-inflammatory effects in different contexts, dependent on its interaction with NF-ĸB 109 . In several studies, activation of β-catenin was shown to inhibit IL-1β and the subsequent production of IL-6 and matrix metalloproteinases (MMPs), resulting in an anti-inflammatory effect 110, 111 . Although its role in sepsis pathogenesis is yet to be fully elucidated, patients with severe sepsis and sepsis-driven ARDS had increased levels of Wnt5A in lung tissue and serum 112 .

However, in bronchial epithelial cells, inhibition of beta-catenin's activation of NF-ĸB resulted in fewer proinflammatory cytokines and cell injury 113 . In a previous unpublished analysis using the same combinatorial approach on a Sjögren's Syndrome cohort found in the UK Biobank, we identified a significant number of genes involved in the Wnt/β-catenin pathway. As with severe COVID-19, patients with Sjögren's syndrome also present with elevated cytokines and inflammation-driving pathology 114 .

The Wnt/ β -catenin pathway has also been implicated in promoting viral replication. In a model of influenza (H1N1), activation of this pathway resulted in higher viral replication and inhibition of Wnt/ β -catenin signalling using iCRT14 reduced viral production and improved clinical symptoms 115 . It has been demonstrated that Rift Valley Virus exploits the proliferative cell state that activation of Wnt signalling promotes to enable viral replication through easier trafficking of viral proteins within the cell. It has also been shown that coronaviruses use this mechanism in proliferative cells 116 . Therefore, inhibition of the Wnt/β-catenin pathway may help limit SARS-CoV-2 replication and reduce viral load in this way. This theory is supported by the fact that niclosamide -an anti-helminthic drug -limits coronavirus replication in a model of SARS 117 . The study did not investigate how this drug inhibited viral replication, but a subsequent study has revealed that niclosamide is an inhibitor of the Wnt signalling pathway 118 . Due to the significant number of genes found to regulate this pathway in our analysis, we believe that modulation of this pathway could be of benefit to a large number of patients who develop severe COVID-19.

There is emerging evidence that key genes associated with Alzheimer's Disease (AD) risk such as APOE4 are associated with increased risk of severe COVID-19 disease, although the reasons for this link are still unclear 119 . Our analysis identified a strong conserved signal for four genes that also confer greater risk of developing AD, including MAPT.

We also found three additional genes that were significant in a previous neurodegenerative disease study we performed. This unpublished study identified 33 genes variants in which were highly associated in cases with sporadic amyotrophic lateral sclerosis (ALS). We have also shown that increasing the activity of two of these genes targets in a mixed cell neuronal assay containing SOD1 reactive astrocytes significantly improves motor neurone survival. This could indicate shared biological pathways that drive both severe COVID-19 and neurodegeneration, potentially through pro-inflammatory, neurotoxic mechanisms. However, the SNP variants found in these genes were not highly enriched in the few severe COVID-19 patients who had been diagnosed with AD. This is probably due to the relatively low numbers of cases diagnosed with AD in UK Biobank as a whole.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 19, 2020. . https://doi.org/10.1101/2020.06.17.20134015 doi: medRxiv preprint

We performed this analysis using only genetic data from patients found in the UK Biobank, identifying 68 protein coding genes that are highly associated with the development of severe COVID-19. These targets would not have been found using standard analytical approaches such as GWAS on the same population. In addition to this, we have identified 29 drugs and clinical candidates and a further eight targets with chemical starting points that could be used in the development of treatment strategies that improve clinical outcomes in severe COVID-19 patients.

It appears that the variants we found in genes relating to immune response pathways and cytokine production cascades were in equal proportions across all severe COVID-19 patients, regardless of their co-morbidities. This suggests that such variants are not associated with any specific co-morbidity, but are common amongst patients who develop severe COVID-19. In contrast there were small deviations in the penetrance of some of the SNPs identified in different co-morbidity cohorts. While the pattern of these deviations were similar across cardiovascular, diabetes and hypertension co-morbidity cohorts, the pattern across the respiratory co-morbidity cohort was somewhat different. These differences, while suggestive of the need for further study, were not yet significant enough to be reported in detail.

As more test records and additional medical data become available in the UK Biobank and other data sources, we will be able to fully ascertain the severe and mild COVID-19 cases and provide an additional layer of validation to the results from this study.

One limitation of the UK Biobank dataset is that the ethnicity distribution of the participants is heavily skewed to white British participants and it has consequently not been possible to fully investigate additional risk factors in BAME patients. We are actively seeking to investigate severe COVID-19 risk factors in other datasets with more ethnically diverse populations. The addition of more phenotypic and clinical data in our analyses may also be used to gain greater understanding into the association of other observed epidemiological risk factors such as ethnicity, socioeconomic status and prescription medication history with development of severe COVID-19.

An interactive web-based dashboard to track COVID-19 in real time

World Health Organization, WHO Coronavirus Disease (COVID-19) Dashboard

Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol

Identification and Analysis of Shared Risk Factors in Sepsis and High Mortality Risk COVID-19 Patients

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan

Centrality of Sepsis": A Review on Incidence, Mortality, and Cost of Care. Healthcare (Basel)

The UK Biobank resource with deep phenotyping and genomic data

Dynamic linkage of COVID-19 test results between Public Health England's Second Generation Surveillance System and UK

Systematic drug repurposing to enable precision medicine: A case study in breast cancer

Enabled Precision Medicine: Patient Stratification, Drug Repurposing & Combination Therapies (ebook 'AI in Oncology Drug Discovery & Development

Combinations of genetic variants associated with bipolar disorder

Modernizing reference genome assemblies

Impact of a five-dimensional framework on R&D productivity at AstraZeneca

PLINK: a tool set for whole-genome association and population-based linkage analyses

The Gene Ontology Consortium. The Gene Ontology Resource: 20 years and still GOing strong

Anthrax Toxin: Receptor Binding, Internalization, Pore Formation, and Translocation

Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus

Phenotype details for gene 26033 (Homo sapiens, ATRNL1)

Next generation massively parallel sequencing of targeted exomes to identify genetic mutations in primary ciliary dyskinesia. Implications for application to clinical testing

Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C

Kaposi's sarcoma-associated herpesvirus fine-tunes the temporal expression of late genes by manipulating a host RNA quality control pathway

Enhanced response to pulmonary Streptococcus pneumoniae infection is associated with primary ciliary dyskinesia in mice lacking Pcdp1 and Spef2

Pivotal Role of Receptor-Interacting Protein Kinase 1 and Mixed Lineage Kinase Domain-Like in Neuronal Cell Death Induced by the Human Neuroinvasive Coronavirus OC43

NRROS negatively regulates reactive oxygen species during host defence and autoimmunity

Secretory RAB GTPase 3C modulates IL6-STAT3 pathway to promote colon cancer metastasis and is associated with poor prognosis

Post-transcriptional regulator Rbm47 elevates IL-10 production and promotes the immunosuppression of B cells

Elevated Semaphorin 5A correlated with Th1 polarization in patients with chronic immune thrombocytopenia

The brown adipocyte protein CIDEA promotes lipid droplet fusion via a phosphatidic acid-binding amphipathic helix

Genome-wide scan for circulating vascular adhesion protein-1 levels: MACROD2 as a potential transcriptional regulator of adipogenesis

Inactivation of Plin4 downregulates Plin5 and reduces cardiac lipid accumulation in mice

A Secreted Slit2 Fragment Regulates Adipose Tissue Thermogenesis and Metabolic Function

New friends for seipin -implications of seipin partner proteins in the life cycle of lipid droplets

Association between the XKR6 rs7819412 SNP and serum lipid levels and the risk of coronary artery disease and ischemic stroke

Regulatory mechanisms of anthrax toxin receptor 1-dependent vascular and connective tissue homeostasis

The role of HOPX in normal tissues and tumor progression

Recent advances in the molecular mechanism of mitochondrial calcium uptake

Regulatory network analysis of hypertension and hypotension microarray data from mouse model

Protein kinase C beta (PKC beta): normal functions and diseases

S-Nitrosylation of Plastin-3 Exacerbates Thoracic Aortic Dissection Formation via Endothelial Barrier Dysfunction

Rap1GAP2 is a new GTPase-activating protein of Rap1 expressed in human platelets

Synaptotagmin-like protein 1 interacts with the GTPase-activating protein Rap1GAP2 and regulates dense granule secretion in platelets

Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension

Semaphorin 5A promotes angiogenesis by increasing endothelial cell proliferation, migration, and decreasing apoptosis

Induced Pluripotent Stem Cell Model of Pulmonary Arterial Hypertension Reveals Novel Gene Expression and Patient Specificity

SorCS2 facilitates release of endostatin from astrocytes and controls post-stroke angiogenesis

Polymorphisms of steroid 5-alpha-reductase type I (SRD5A1) gene are associated to peripheral arterial disease

Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer

MACROD2 deficiency promotes hepatocellular carcinoma growth and metastasis by activating GSK-3β/β-catenin signaling

Protocadherin 17 functions as a tumor suppressor suppressing Wnt/β-catenin signaling and cell metastasis and is frequently methylated in breast cancer

Protein-kinase-C-mediated beta-catenin phosphorylation negatively regulates the Wnt/beta-catenin pathway

PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin/E-cadherin complexes in cancer cells

Silencing RRM2 inhibits multiple myeloma by targeting the Wnt/β-catenin signaling pathway

NHE9 induces chemoradiotherapy resistance in esophageal squamous cell carcinoma by upregulating the Src/Akt/β-catenin pathway and Bcl-2 expression

Suppression of Slit3 induces tumor proliferation and chemoresistance in hepatocellular carcinoma through activation of GSK3β/β-catenin pathway

ChEMBL: a large-scale bioactivity database for drug discovery

Host Factors in Coronavirus Replication

T cell-mediated immune response to respiratory coronaviruses

The landscape of lung broncheoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing

Persistence of effector memory Th1 cells is regulated by Hopx

Attenuation of immunological symptoms of allergic asthma in mice lacking the tyrosine kinase ITK

Itk inhibitors: a patent review

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma

Selective Itk inhibitors block T-cell activation and murine lung inflammation

Discovery of novel irreversible inhibitors of interleukin (IL)-2-inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocket

Insights into the immuno-pathogenesis of acute respiratory distress syndrome

Selective targeting of ITK blocks multiple steps of HIV replication

Pivotal Role of Receptor-Interacting Protein Kinase 1 and Mixed Lineage Kinase Domain-Like in Neuronal Cell Death Induced by the Human Neuroinvasive Coronavirus OC43

Necrosulfamide inhibits necroptosis by selectively targeting the mixed lineage kinase domain-like protein

Immunomodulation in COVID-19

Identification and characterisation of a unique leucine-rich repeat protein (LRRC33) that inhibits Tolllike receptor-mediated NF-ĸB activation

Editorial: dialing down inflammation: LRRC33 regulates Toll-like receptor signaling

Inflammation and cancer: IL-6 and STAT3 complete the link

Treatment of SARS Caused by COVID-19 with Ruxolitinib. ClinicalTrials.gov identifier: NCT04334044

Endothelial cell infection and endotheliitis in COVID-19. The Lancet

Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions

Endothelial dysfunction in hypertension

Potential effects of coronavirus on the cardiovascular system

Helios: still behind the clouds

Helios but not CD226, TIGIT and Foxp3 is a Potential Marker for CD4 + Treg Cells in Patients with Rheumatoid Arthritis

Down-regulation of Helios Expression in Tregs from Patients with Hypertension

CD4+CD25+Foxp3 regulatory T cells and vascular dysfunction in hypertension

MCUB Regulates the Molecular Composition of the Mitochondrial Calcium Uniporter Channel to Limit Mitochondrial Calcium Overload During Stress

MCUb Induction Protects the Heart from Post-Ischemic Remodelling

Serum calcium as a biomarker of clinical severity and prognosis in patients with coronavirus disease 2019: a retrospective cross-sectional study. 2020;0

Inhibition of Protein Kinase Cβ Prevents Foam Cell Formation by Reducing Scavenger Receptor A Expression in Human Macrophages

Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes

PKCβ and reactive oxygen species mediate enhanced pulmonary vasoconstrictor reactivity following chronic hypoxia in neonatal rats

Protein kinase C beta and delta isoenzymes mediate cholesterol accumulation in PMA-activated macrophages

Ruboxistaurin: LY 333531

Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients

Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin

Eli Lilly and Takeda pull the plug on ruboxistaurin studies

Association between insulin resistance and the development of cardiovascular disease

Cidea is associated with lipid droplets and insulin sensitivity in humans

GFRA1: A Novel Molecular Target for the Prevention of Osteosarcoma Chemoresistance

Ginsenoside Rg3 attenuates sepsis-induced injury and mitochondrial dysfunction in liver via AMPKmediated autophagy flux

The Role of Autophagy in Sepsis: Protection and Injury to Organs

Small-molecule ligands as potential GDNF family receptor agonists

Modulation of Lipid Droplet Metabolism-A Potential Target for Therapeutic Intervention in Flaviviridae Infections

Chapter 10 -Lipid Droplets and Viral Infections

Inhibition of Cytosolic Phospholipase A2α Impairs an Early Step of Coronavirus Replication in Cell Culture

Modulation of Lipid Droplet Metabolism-A Potential Target for Therapeutic Intervention in Flaviviridae Infections

TIP47 plays a crucial role in the life cycle of hepatitis C virus

Role of seipin in lipid droplet morphology and hepatitis C virus life cycle

Crosstalk between Wnt/β-Catenin and NF-κB Signaling Pathway during Inflammation

beta-Catenin activity negatively regulates bacteria-induced inflammation

A Wnt/β-catenin negative feedback loop inhibits interleukin-1-induced matrix metalloproteinase expression in human articular chondrocytes

Functions of the WNT Signaling Network in Shaping Host Responses to Infection

Crosstalk between Wnt/β-Catenin and NF-κB Signaling Pathway during Inflammation

Elevated cytokine levels in tears and saliva of patients with primary Sjögren's syndrome correlate with clinical ocular and oral manifestations

Regulation of influenza virus replication by Wnt/β-catenin signaling

Cell cycle dependent nucleolar localization of the coronavirus nucleocapsid protein

Inhibition of Severe Acute Respiratory Syndrome Coronavirus Replication by Niclosamide

Inhibition of canonical WNT signaling attenuates human leiomyoma cell growth

APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort

We would like to acknowledge UK Biobank for providing us access to the data under Application ID 44288 and Bugbank for linking infection data from Public Health England to improve the study of infection in the UK Biobank cohort.

1. Controls to exclude any patients with the following ICD-10 codes:

Disease A02. 1 Salmonella septicemia A22. 7 Anthrax septicemia A40.x Streptococcal septicemia A41.x Other septicemia B37. 7 Candidal septicemia O35Puerperal sepsis R57. 2 Septic shock 2. Controls to include at least one of the following ICD-10 codes:Lower respiratory infection B95 Streptococcus B95 Staphylococcus 3. Controls to include least one of the following ICD-10 codes:Liver Disease J40-J44 COPD 

Cases with co-morbidities were identified using the following disease codes: